Home > Insider Trading > Filing (0000950142-12-001608)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1544116	Durata Therapeutics Inc.	DRTX	Pharmaceutical Preparations (2834)	871247903

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1172252	N Andrew Schiff	888 Seventh Avenue, 30Th Fl New York NY 10106	No	No	Yes	No
1250195	Steve Elms	888 Seventh Avenue, 30Th Fl New York NY 10106	No	No	Yes	No
1297291	J Dennis Purcell	888 Seventh Avenue, 30Th Fl New York NY 10106	No	No	Yes	No
1444717	Aisling Capital Iii Lp	888 Seventh Avenue, 30Th Fl New York NY 10106	No	No	Yes	No
1532634	Aisling Capital Partners Iii Lp	888 Seventh Avenue, 30Th Fl New York NY 10106	No	No	Yes	No
1532635	Aisling Capital Partners Iii Llc	888 Seventh Avenue, 30Th Fl New York NY 10106	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2012-07-24	2,019,713	$0.00	2,019,713	No	4	C	Indirect	By Aisling Capital III, LP
Common Stock	Acquisiton	2012-07-24	1,111,111	$9.00	3,130,824	No	4	P	Indirect	By Aisling Capital III, LP

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Aisling Capital III, LP
No	4	P	Indirect	By Aisling Capital III, LP

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2012-07-24	16,157,707	$0.00	2,019,713	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Footnotes

On July 24, 2012, Aisling Capital III, LP ("Aisling") acquired 2,019,713 shares of common stock issued upon the conversion of 16,157,707 shares of Series A Preferred Stock at the closing of Durata Therapeutics, Inc.'s initial public offering of common stock ("IPO") for no additional cost.
These shares of common stock are owned directly by Aisling, and held indirectly by Aisling Capital Partners III, LP ("Aisling GP") , as general partner of Aisling, Aisling Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners and the Managers share voting and dispositive power over the shares directly held by Aisling.
On July 24, 2012, Aisling acquired 1,111,111 shares of common stock in the IPO.
Series A preferred stock was convertible into common stock at the option of the holder or upon the completion of the IPO and had no expiration date.
Series A preferred stock was owned directly by Aisling, and held indirectly by Aisling GP, as general partner of Aisling, Aisling Partners, as general partner of Aisling GP, and each of the Managers. After the conversion of Series A preferred stock reported hereby, Aisling, Aisling GP, Aisling Partners and each of the Managers no longer hold any shares of Series A preferred stock.